Skip to content
Companies

Newleos Therapeutics

Drugs for anxiety and substance use disorders

Raised to date

$93.4M

of $93.4M offered across 1 Form D filing

Investors
11
Last filed
Feb 24, 2025

About

Newleos Therapeutics, Inc. is a pioneering clinical-stage neuroscience company focused on the innovation of therapies for neuropsychiatric disorders. With a commitment to addressing the pressing unmet needs in mental health, Newleos is dedicated to developing effective tools for anxiety and substance use disorders, impacting millions across the United States.

Newleos stands out for its focus on first-in-class therapies that target novel mechanisms, aiming to reduce side effects compared to current treatment options.

Funding

  • EquityFiled Feb 24, 2025Form D
    $93.4M/ $93.4M

Product

NTX-1955

Mental Health Therapy

NTX-1955 is a groundbreaking GABA A -γ1 selective positive allosteric modulator that represents the company's lead clinical program aimed at treating anxiety disorders. This molecule is designed to help mitigate anxiety symptoms with potentially fewer side effects compared to traditional therapies.

  • First-in-class mechanism targeting GABA A -γ1
  • Oral small molecule formulation
  • Designed with a focus on reducing side effects

Built for

Individuals suffering from neuropsychiatric disorders, particularly anxiety and substance use disorders.

People on file